3 cancer drugs from AstraZeneca set to enter late-stage trials

05/17/2013 | Bloomberg Businessweek

AstraZeneca plans to advance its three cancer drug candidates into Phase III trials. Set to advance are moxetumomab pasudotox for patients with hairy cell leukemia, selumetinib for patients with KRAS-positive nonsmall-cell lung cancer, and olaparib for patients with platinum-sensitive relapsed ovarian cancer. The firm also plans to double the number of drugs in its late-stage pipeline and submit three regulatory applications by 2016.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA